Viking Therapeutics (VKTX) Announces Presentation of Positive VK5211 Phase 1 Data in Muscle and Bone Disorders
Tweet Send to a Friend
Viking Therapeutics, Inc. (Nasdaq: VKTX) announced the presentation of data from a Phase 1 trial of VK5211, the company's lead ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
